These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27076626)

  • 1. A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.
    Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Fairbrother WJ; Wong H; Budha N; Darbonne WC; Peale F; Mamounas M; Royer-Joo S; Yu R; Portera CC; Infante JR
    Clin Cancer Res; 2016 Sep; 22(18):4567-73. PubMed ID: 27076626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
    Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
    Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
    Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
    Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
    Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
    Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
    Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
    Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.
    Hurwitz HI; Smith DC; Pitot HC; Brill JM; Chugh R; Rouits E; Rubin J; Strickler J; Vuagniaux G; Sorensen JM; Zanna C
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):851-9. PubMed ID: 25716544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
    Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
    Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
    Das M; Padda SK; Frymoyer A; Molina J; Adjei A; Lensing JL; Miles D; Sikic BI; Wakelee HA
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):541-550. PubMed ID: 30030583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
    Wagner AJ; Messersmith WA; Shaik MN; Li S; Zheng X; McLachlan KR; Cesari R; Courtney R; Levin WJ; El-Khoueiry AB
    Clin Cancer Res; 2015 Mar; 21(5):1044-51. PubMed ID: 25388167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
    Brunetto AT; Ang JE; Lal R; Olmos D; Molife LR; Kristeleit R; Parker A; Casamayor I; Olaleye M; Mais A; Hauns B; Strobel V; Hentsch B; de Bono JS
    Clin Cancer Res; 2013 Oct; 19(19):5494-504. PubMed ID: 24065624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
    Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
    J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
    Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
    Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
    Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
    Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
    Sarker D; Molife R; Evans TR; Hardie M; Marriott C; Butzberger-Zimmerli P; Morrison R; Fox JA; Heise C; Louie S; Aziz N; Garzon F; Michelson G; Judson IR; Jadayel D; Braendle E; de Bono JS
    Clin Cancer Res; 2008 Apr; 14(7):2075-81. PubMed ID: 18381947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
    Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
    J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.